1. Home
  2. Mandates
  3. New issue in AttgeNO

Mandate New issue in AttgeNO

May 02, 2018

The Swedish pharmaceutical research company AttgeNO has performed a new issue of shares.

AttgeNO works on the development of new pharmaceuticals which expand blood vessels. Supernitro (PDNO) is a new, patented pharmaceutical candidate for treatment of acute and life-threatening high blood pressure in the lungs, which, can arise for example in connection with heart surgery and may result in death. The capital generated as a result of the new issue of shares is intended to give AttgeNO an opportunity to perform clinical Phase 1 studies during 2019.

AttgeNO was advised by partner Johan Winnerblad.

Vinge in first place when the transaction year 2020 is summarized
January 07, 2021

Sanctions round-up

Not long time ago sanctions were a rare occurrence which only involved obscure products and countries, and which were decided by the members of the United Nations Security Council. Today, the European Union and, in particular, the United States, impose sanctions and other trade restrictions with high frequency which have the potential to affect any type of transaction. Below you will find a summary of some recent developments.
December 22, 2020

EU Commission criticizes Sweden for its application of the rules on combined transports

 Through a formal notice to Sweden, the European Commission has criticized the inadequate application of Directive 92/106/ECC on common rules for certain forms of combined transport of goods between Member States (the “Combined Transports Directive”). The notice mainly concerns the Swedish Transport Agency's application of the term "nearest suitable railway station"
December 11, 2020